Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Long-Term Deferred Tax (2018 - 2020)

Protagonist Therapeutics' Long-Term Deferred Tax history spans 3 years, with the latest figure at $1.1 million for Q1 2020.

  • For Q1 2020, Long-Term Deferred Tax rose 126.36% year-over-year to $1.1 million; the TTM value through Mar 2020 reached $1.1 million, up 126.36%, while the annual FY2019 figure was $1.4 million, 117.78% up from the prior year.
  • Long-Term Deferred Tax for Q1 2020 was $1.1 million at Protagonist Therapeutics, down from $1.4 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $2.1 million in Q3 2019 and bottomed at $478000.0 in Q1 2019.
  • The 3-year median for Long-Term Deferred Tax is $1.3 million (2019), against an average of $1.3 million.
  • The largest annual shift saw Long-Term Deferred Tax skyrocketed 117.78% in 2019 before it surged 126.36% in 2020.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $658000.0 in 2018, then surged by 117.78% to $1.4 million in 2019, then fell by 24.49% to $1.1 million in 2020.
  • Per Business Quant, the three most recent readings for PTGX's Long-Term Deferred Tax are $1.1 million (Q1 2020), $1.4 million (Q4 2019), and $2.1 million (Q3 2019).